The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes

Neoplasma

Volumn 57, Issue 6, 2010, Pages 530-536

  Reis Alves, S C ^a   Traina, F ^a   Saad, S T O ^a   Metze, K ^a   Lorand Metze, I ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

B cell precursors; Flow cytometry; IPSS; MDS; Myelodysplastic syndrom; Survival

Indexed keywords

ADULT; ARTICLE; BASOPHIL; BLOOD CELL COUNT; BONE MARROW; CD34+ T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; T LYMPHOCYTE; AGED; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; MORTALITY; RISK FACTOR;

CD34 ANTIGEN;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS;

EID: 79952114743     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_06_530     Document Type: Article

References (28)

1. SWERDLOW S, CAMP E, HARRIS N, ET AL WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC, 2008
2. GREENBERG P, COX C, LEBEAU MM, FENAUX P, MOREL P et al. International scoring system for evaluation in MDS. Blood 1997; 89: 2079-88.
3. VAN LOCHEM EG, VELDEN VHJ, WIND JG, MARVELDE JG, WESTERDAAL NAC et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B 2004; 60: 1-13. doi:10.1002/cyto.b.20008
4. STETLER-STEVENSON M, YUAN CM. Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis. Int J LAB HEMATOl 2009; 31: 479-483. doi:10.1111/j.1751-553X.2009.01176.x
5. MATARRAZ S, LOPEZ A, BARRENA S, FERNANDEZ C, JENSEN E et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008; 22: 1175-83. doi:10.1038/leu.2008.49
6. WELLS DA, BENESCH M, LOKEN MR, VALLEJO C, MYERSON D et al. Myeloid and monocytic dispoiesis as determinated by flow cytometry scoring in myelodysplastic syndromes correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood. 2003; 102: 394-405. doi:10.1182/blood-2002-09-2768
7. ORFAO A, ORTUÑO F, SANTIAGO M, LOPEZ A, MIGUEL J. Immunophenotyping of Acute Leukemias and Myelodysplastic Syndromes. Cytometry A. 2004; 58: 62-71. doi:10.1002/cyto. a.10104
8. Kussick SJ, Fromm JR, Rossini A, Li Y, Chang A et al. Fourcolor flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol. 2005; 124: 170-81. doi:10.1309/6PBP78G4FBA1FDG6
9. OGATA K, KISHIKAWA Y, SATOH C, TAMURA H, DAN K et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood. 2006; 108: 1037-44. doi:10.1182/blood-2005-12-4916
10. PIRRUCELLO SJ, YOUNG KH, AOUN P. Myeloblast phenotypic changes in myelodysplasia. Am J Clin Pathol. 2006; 125: 884-94. doi:10.1309/J3ET7RXD1X4BKDLF
11. LORAND-METZE I, RIBEIRO E, LIMA CSP, BATISTA LS, METZE K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007; 31: 147-55. doi:10.1016/ j.leukres.2006.04.010
12. SATOH C, DAN K, YAMASHITA T, JO R, TAMURA H et al. Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 2008; 32: 699-707. doi:10.1016/j.leukres.2007.08.022
13. STACHURSKI D, SMITH BR, POZDNYAKOVA O, ANDERSEN M, XIAO Z et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: Emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008; 32: 215-24. doi:10.1016/j.leukres.2007.06.012
14. VALENT P, HORNY HP, BENNETT JM, FONATSCH C, GERMING U et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727-39. doi:10.1016/j.leukres.2006.11.009
15. LOKEN MR, VAN DE LOOSDRECHT A, OGATA K, ORFAO A, WELLS DA. Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leuk Res 2008; 32: 5-17. doi:10.1016/j.leukres.2007.04.020
16. VAN DE LOOSDRECHT AA, ALHAN C, BÉNÉ MC, DELLA PORTA MG et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometric in myelodysplastic syndromes. Haematologica. 2009; 94: 1124-34. doi:10.3324/haematol.2009.005801
17. REIS SC, TRAINA F, METZE K, SAAD ST, LORAND-METZE I. Variation of bone marrow CD34+ cell subsets in myelodysplastic syndromes according WHO types. Neoplasma. 2009; 56: 435-40. doi:10.4149/neo_2009_05_435
18. LORAND-METZE I, CALIFANI SMV, RIBEIRO E, LIMA CSP, METZE K. The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leuk Res 2008; 32: 211-3. doi:10.1016/j.leukres.2007.06.014
19. RIBEIRO E, MATARRAZ SUDÓN S, SANTIAGO M, LIMA CSP, METZE K et al. Maturation-associated immnophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leukemia Research. 2006; 30: 9-16. doi:10.1016/j.leukres.2005.05.019
20. LORAND-METZE I, PINHEIRO MP, RIBEIRO E, DE PAULA EV, METZE K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: Comparison of FAB and WHO classifications. Leuk Res 2004; 28: 587-94. doi:10.1016/ j.leukres.2003.11.001
21. DELAMAIN MT, MARQUES JR JFC, DE SOUZA CA, LORAND-METZE I, METZE K. An algorithm based on peripheral CD34+ cells and hemoglobin concentration provides a better optimization of apheresis than the application of a fixed CD34 threshold. Transfusion 2008; 48: 1133-1137. doi:10.1111/j.1537-2995.2008.01687.x
22. BABUSIKOVA O, ZELEZNIKOVA T. Normal maturation sequence of immunoglobulin light and heavy chains in hematogone stages 1, 2 and 3 in acute leukemia after treatment. Neoplasma 2008; 55: 501-505.
23. MAFTOUN-BANANKHAH S, MALEKI A, KARANDIKAR NJ, ARBINI AA, FUDA FS et al. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes. Am J Clin Pathol. 2008; 129: 300-8. doi:10.1309/4W2G3NDXUPG5J33N
24. VAN DE LOOSDRECHT A, WESTERS TM, WESTRA AH, DRÄGER AM, VAN DER VELDEN VHJ, OSSENKOPPELE GJ. Identification of distinct subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood. 2008; 111: 1067-77. doi:10.1182/blood-2007-07-098764
25. LORAND-METZE I, PINHEIRO MP, RIBEIRO E, DE PAULA EV, METZE K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: Comparison of FAB and WHO classifications. Leuk Res 2004; 28: 587-94. doi:10.1016/ j.leukres.2003.11.001
26. KUSENDA J. Quantitative identification of blood cell markers in human hematopoietic malignancies with diagnostic and prognostic significance. Neoplasma 2008; 55: 381-386.
27. VASIKOVA A, BUDINSKA E, BELICKOVA M, CERMAK J, BRUCHOVA H. Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome. Neoplasma 2009; 56: 335-342. doi:10.4149/neo_2009_04_ 335
28. RIBEIRO E, LIMA CSP, METZE K, LORAND-METZE I. Flow cytometric analysis of the expression of Fas/Fasl in bone marrow CD34+ cells in myelodysplastic syndromes: relation to disease progression". Leuk & Lymph 2004; 45: 309-313. doi:10.1080/10428190310001598044